These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
399 related articles for article (PubMed ID: 37339882)
1. Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor. Zhang Y Pharmacol Rev; 2023 Nov; 75(6):1218-1232. PubMed ID: 37339882 [TBL] [Abstract][Full Text] [Related]
2. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374 [TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Yewale C; Baradia D; Vhora I; Patil S; Misra A Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842 [TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102 [TBL] [Abstract][Full Text] [Related]
8. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer. Zhang K; Yuan Q J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005 [TBL] [Abstract][Full Text] [Related]
9. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Nguyen KS; Kobayashi S; Costa DB Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948 [TBL] [Abstract][Full Text] [Related]
10. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. Regales L; Gong Y; Shen R; de Stanchina E; Vivanco I; Goel A; Koutcher JA; Spassova M; Ouerfelli O; Mellinghoff IK; Zakowski MF; Politi KA; Pao W J Clin Invest; 2009 Oct; 119(10):3000-10. PubMed ID: 19759520 [TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor as a therapeutic target in glioblastoma. Kalman B; Szep E; Garzuly F; Post DE Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987 [TBL] [Abstract][Full Text] [Related]
12. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Oxnard GR; Arcila ME; Chmielecki J; Ladanyi M; Miller VA; Pao W Clin Cancer Res; 2011 Sep; 17(17):5530-7. PubMed ID: 21775534 [TBL] [Abstract][Full Text] [Related]
13. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Roskoski R Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458 [TBL] [Abstract][Full Text] [Related]
15. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653 [TBL] [Abstract][Full Text] [Related]
16. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Takezawa K; Pirazzoli V; Arcila ME; Nebhan CA; Song X; de Stanchina E; Ohashi K; Janjigian YY; Spitzler PJ; Melnick MA; Riely GJ; Kris MG; Miller VA; Ladanyi M; Politi K; Pao W Cancer Discov; 2012 Oct; 2(10):922-33. PubMed ID: 22956644 [TBL] [Abstract][Full Text] [Related]
17. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Yano S; Takeuchi S; Nakagawa T; Yamada T Cancer Sci; 2012 Jul; 103(7):1189-94. PubMed ID: 22435662 [TBL] [Abstract][Full Text] [Related]
18. Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities. Maity P; Chatterjee J; Patil KT; Arora S; Katiyar MK; Kumar M; Samarbakhsh A; Joshi G; Bhutani P; Chugh M; Gavande NS; Kumar R J Med Chem; 2023 Mar; 66(5):3135-3172. PubMed ID: 36812395 [TBL] [Abstract][Full Text] [Related]
19. Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer. Tripathi SK; Pandey K; Rengasamy KRR; Biswal BK Med Res Rev; 2020 Nov; 40(6):2132-2176. PubMed ID: 32596830 [TBL] [Abstract][Full Text] [Related]
20. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Bianco R; Troiani T; Tortora G; Ciardiello F Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S159-71. PubMed ID: 16113092 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]